Publications by authors named "Nanna M Madsen"
Article Synopsis
- Antipsychotic polypharmacy, or the use of multiple antipsychotic medications, is common in clinical practice, but it carries a higher risk of side effects and there's little proof that it works better than using a single medication.
- A systematic review analyzed 517 studies involving over 4.4 million individuals to determine the prevalence and trends of antipsychotic polypharmacy across different mental disorders.
- The findings revealed that 24.8% of individuals were using multiple antipsychotics, with higher rates in those with schizophrenia spectrum disorders and significant regional variations, showing an overall trend of increasing polypharmacy from 1970 to 2023.
Background: Antipsychotics increase the risk of developing diabetes, but clinical trials are not generalizable with short follow-up, while observational studies often lack important information, particularly hemoglobin A1c (HbA1c).
Methods: We followed two Danish cohorts with schizophrenia. First, using Danish nationwide registers, we identified all individuals diagnosed with first-episode schizophrenia (FES) between 1999 and 2019 (n = 31,856).
We aimed to identify diagnosis-specific/transdiagnostic/transoutcome multivariable candidate predictors (MCPs) of key outcomes in mental disorders. We conducted an umbrella review (protocol link ), searching MEDLINE/Embase (19/07/2022), including systematic reviews of studies reporting on MCPs of response, remission, recovery, or relapse, in DSM/ICD-defined mental disorders. From published predictors, we filtered MCPs, validating MCP criteria.
View Article and Find Full Text PDF